Scheid, C., Sonneveld, P., Schmidt-Wolf, I. G., van der Holt, B., el Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Blau, I. W., Vellenga, E., Weisel, K., Pfreundschuh, M., Jie, K.-S., Neben, K., van de Velde, H., Duehrsen, U., Schaafsma, M. R., Lindemann, W., Kersten, M. J., Peter, N., Hänel, M., Croockewit, S., Martin, H., Wittebol, S., Bos, G. M., van Marwijk-Kooy, M., Wijermans, P., Goldschmidt, H. and Lokhorst, H. M. (2014) “Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial”, Haematologica. Pavia, Italy, 99(1), pp. 148-154. doi: 10.3324/haematol.2013.087585.